阿尔茨海默病的治疗:超越症状疗法
Francesca R Buccellato1,2, Marianna D'Anca2, Gianluca Martino Tartaglia1,2
1Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.
International journal of molecular sciences
|September 28, 2023
概括
阿尔茨海默病 (AD) 的治疗方法正在发展,超越了症状管理. 针对粉样质斑块的新型疾病修饰疗法 (DMT) 与非药理学方法和早期检测生物标志物一起显示出希望.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默氏症 (AD) 是全球痴呆的主要原因,影响数百万,并构成重大公共卫生挑战.
- 目前的AD治疗主要集中在使用乙胆酶抑制剂和Memantine的症状管理上,结合疗法旨在增强认知储备.
- 这种疾病的特点是积累β-粉样化合物和高酸化蛋白.
研究的目的:
- 审查正在进行的疾病修饰疗法 (DMT) 和阿尔茨海默病的非药物干预的临床试验.
- 基于早期检测预临床和前期AD阶段生物标志物的进展,探索未来的治疗场景.
主要方法:
- 审查最近的临床试验涉及DMT和阿尔茨海默病的非药物治疗方法.
- 分析新兴的生物标志物用于早期AD检测和风险识别.
- 讨论潜在的未来治疗策略对AD.
主要成果:
- 美国食品和药物管理局对阿杜卡努马布的条件批准和莱卡内马布的加速批准标志着针对Aβ斑块的DMT的新时代.
- 目前正在进行的试验正在评估各种DMT的疗效和安全性,以及补充的非药理学方法.
- 生物标志物研究正在推进早期诊断和介入阿尔茨海默病的潜力.
结论:
- 最近对单克隆抗体的批准代表了对阿尔茨海默氏症疾病修饰治疗的重大转变.
- 新兴的DMT,非药物战略和通过生物标志物的早期检测的结合为AD管理提供了有希望的未来.
- 随着诊断和治疗方面的进步,早期和潜在的治愈治疗正在成为一个现实的目标.
相关概念视频
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
01:26Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
01:24Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
01:28Drug Therapy
60
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
60
01:15Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
147
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
147